Clinical Trials · NCT07516704

Safety and Efficacy of Docetaxel, Darolutamide, and Homoharringtonine Combined With Androgen Deprivation Therapy in Neoadjuvant Treatment of High-Risk Prostate Cancer: A Multicenter Prospective, Single-Arm Clinical Study

Name: Safety and Efficacy of Docetaxel, Darolutamide, and Homoharringtonine Combined With Androgen Deprivation Therapy in Neoadjuvant Treatment of High-Risk Prostate Cancer: A Multicenter Prospective, Single-Arm Clinical Study
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

Not Yet RecruitingEARLY_Phase 1Gonadorelin

Phase: EARLY_Phase 1
Recruitment status: Not Yet Recruiting
Sponsor: Zhongda Hospital
Enrollment: 94
Start date: Apr 2026
Locations: See registry
Primary endpoint: pCR or MRD Rate

View Gonadorelin compound reference